Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 in localised prostate cancer
NCT02064608Phase 1Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2014
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of vistusertib in prostate cancer (PCa), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Percentage change from baseline in mTORC1 and mTORC2 signaling at 2 weeks. Started Oct 2014; status: completed.
02
Drugs
vistusertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02064608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064608.